NCT07294664 2026-04-16
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
Clinical Trials
20 trialsNCT07517653 2026-04-08
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07503639 2026-03-31
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07464756 2026-03-11
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT07451795 2026-03-05
SHARP
Fudan University
Phase 2 Recruiting
NCT05671822 2026-02-12
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07355010 2026-01-21
A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT07311408 2025-12-31
SHR-2554
China Medical University, China
Phase 2 Recruiting
NCT07175220 2025-11-18
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT07102901 2025-09-10
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT06679673 2024-11-07
SHR-1701 Combined with SHR2554 and BP102 for MCRC
Fudan University
Phase 2 Not yet recruiting
NCT04699968 2023-06-07
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT05106023 2023-06-07
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
Fudan University
Phase 2 Unknown
NCT04580498 2023-05-19
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT05177497 2022-01-04
SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC
Shanghai Chest Hospital
Phase 2 Unknown
NCT04650633 2021-10-29
SHR-1701 in Patients With Recurrent/Metastatic Scchn
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04884009 2021-05-12
A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04560244 2020-09-23
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
Shandong Cancer Hospital and Institute
Phase 2 Unknown